Last Updated on October 9, 2024 by The Health Master
The Subject Expert Committee (SEC) of the Central Drugs Standard Control Organisation (CDSCO) has granted permission to Sun Pharma Ltd to conduct a phase III clinical trial for its antipsychotic drug pimavanserin in India.
Permission was granted in a meeting held by the New Drug Division of SEC on January 18 at the CDSCO headquarters in New Delhi. The company submitted a revised phase III clinical trial protocol before the Committee following the latter’s recommendation in a meeting held on November 18, 2021.
The application submitted by Sun Pharma is for pimavanserin capsules, 34 mg.
“After detailed deliberation, the committee recommended the grant of permission to conduct the phase III clinical trial,” said the minutes of the SEC meeting.
It may be noted that the company has earlier presented their proposal for BE waiver and local clinical trial waiver along with justification for the waiver and published data in support of the safety and efficacy of the drug.
However, a meeting held on August 6, 2020, recommended that a phase III clinical trial be conducted, and accordingly, the protocol should be submitted for review by the committee.
Pimavanserin, which is sold under the brand name Nuplazid, is an atypical antipsychotic drug for the treatment of complications related to Parkinson’s disease. Other Indian companies are also looking at exploring the market potential of the drug.
Zydus Cadila, in December, 2021, announced that it has received tentative approval from the US FDA to market pimavanserin tablets, 10 mg.
“Pimavanserin is used to treat the symptoms of a certain mental/mood disorder (psychosis) that might occur with Parkinson’s disease. It helps lessen symptoms such as seeing or hearing things that are not there (hallucinations) and false beliefs (delusions),” said a company release.
Zydus said that the drug will be manufactured at the group’s formulation manufacturing facility at the SEZ, Ahmedabad.
Notifications: New Drugs, FDC, Clinical Trial
Other details about New Drugs, FDCs, Clinical trial
Govt amends Drug Rules to include liquid antiseptic under Schedule K
Govt issues draft amendment in Rule 8 under New Drugs and Clinical Trials Rules 2019
USFDA gives Orphan Drug Designation to Eplontersen
NDPS Online portal for submission of applications for export & import
R&D Policy for Pharma may be announced
USFDA’s response on Chronic Cough treatment
India and Pharmacy Education: Chapter: 12
Mylan Pharma recalled Insulin Glargine inj due to this reason
Govt issued draft notification to amend Rule 43 of MD Rules 2017
Latest Notifications regarding Pharmaceuticals
For informative videos by The Health Master, click on the below YouTube icon:
For informative videos on Medical Store / Pharmacy, click on the below YouTube icon:
For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:
For informative videos on consumer awareness, click on the below YouTube icon:
